Understand the source comparison
Lose Weight After Menopause with Peptides: Protocol Comparison
Semaglutide GLP-1 agonist 0.25–2.4mg weekly 10–15% body weight First-line therapy, strong evidence base GI side effects during titration Tirzepatide Dual GIP/GLP-1 agonist 2.5–15mg weekly 15–21% body weight Higher efficacy needed, prior GLP-1 non-response Cost
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Semaglutide
- GLP-1 agonist
- 0.25–2.4mg weekly
- 10–15% body weight
- First-line therapy, strong evidence base
- GI side effects during titration
- Tirzepatide
- Dual GIP/GLP-1 agonist
- 2.5–15mg weekly
- 15–21% body weight
- Higher efficacy needed, prior GLP-1 non-response
- Cost (3–4× semaglutide)
- MK-677
- Growth hormone secretagogue
- 10–25mg daily
- 2–5% body weight
- Muscle preservation, indirect fat loss
- Does not suppress appetite
- Tesofensine
- Triple monoamine reuptake inhibitor
- 0.25–1mg daily
- 8–11% body weight
- Energy expenditure boost
- Not FDA-approved, cardiovascular monitoring required
- CJC-1295/Ipamorelin
- Growth hormone release
- 300mcg each, 5x weekly
- 3–6% body weight
- Adjunct to GLP-1 therapy, lean mass retention
- Minimal standalone fat loss